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estimated opportunity loss due to uncertainty, compared with the situation in 
which the evidence was synthesized using traditional pairwise meta-analysis. 
The nominal value of EVPIs varied considerably between the two schemes, with 
potential to have an impact on the justifiability and the optimal sample size of 
the future RCT.  
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OBJECTIVES: In cost-effectiveness literature, several Markov models with 
different health states and assumptions are used to estimate cost-effectiveness 
for treatment of advanced breast cancer (ABC). This study aims to (1) derive the 
relationships among the Markov models for ABC, and (2) examine the impact of 
using different Markov models on cost-effectiveness results for treatment of 
HER2-positive advanced breast cancer. METHODS: There are four Markov models 
for ABC: (i) model 1 includes 4 health states (stable, response, progression, and 
dead) with a possibility of death can occur in all health states; (ii) model 2 also 
consists of 4 health states but the chance of dying can only occur at disease-
progression state; (iii) model 3 is the most common model and has 3 health 
states (stable, progression, and dead) with a possibility of death can occur in all 
health states; and (iv) model 4 also has 3 health states but the chance of death 
can only occur at disease-progression state. Relationships of transition 
probabilities among the Markov models were derived. A simulation method was 
used to generate 10,000 samples with transition probabilities, estimated costs 
and utilities for each health state based on a previously published cost-
effectiveness study of lapatinib in treatment of HER2-positive advanced breast 
cancer. RESULTS: Markov models 2 and 4 yielded similar and lowest incremental 
cost-effectiveness ratios (ICER), while the commonly used Markov model (model 
3) produced the highest ICER. All four Markov models produced ICERs > $150,000 
per additional quality-adjusted life year gained for the combination therapy with 
lapatinib as compared to monotherapy with capecitabine. CONCLUSIONS:  
This study suggests that modeling advanced breast cancer with different health-
state Markov models may produce different cost-effectiveness results. 
Combination therapy with lapatinib in treatment of HER2-positive advanced 
breast cancer is not a cost-effective treatment strategy regardless which Markov 
models used.  
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OBJECTIVES: Economic modeling and health care cost analyses are used to 
inform policy-makers in health care decision-making such as cost-of-illness 
assessments, treatment evaluation studies, and more commonly to predict 
health care costs for specific patient populations. However, due to stochastic 
error distribution assumptions and the challenges they create for econometric 
modeling, various types of models have been identified to address specific 
distributional characteristics. The objective of study is to examine cost 
distributions for treated diabetes patients and compare untransformed ordinary 
least squares (OLS) regression with log transformed OLS and generalized linear 
model (GLM) methods. METHODS: A simulated distribution was created 
mirroring a representative claims dataset for type 2 diabetes costs. Using 
simulated cost distributions with known error term ensures that model selection 
could be assessed with certainty of the error specification for the distribution. 
Two simulated cost distributions were generated: one with homoskedastic errors 
and the other with heteroskedastic errors. Both distributions were used to 
explore model performance under varying conditions. Several tests for model fit, 
specification, and predictive ability were selected from the existing literature to 
assess model selection and determine best model fit. Simulation and all analyses 
were done using STATA 11. RESULTS: Results from the model specification tests 
indicate that for both cost error distributions, OLS regression on untransformed 
Y is the best-fitting model of the three tested. Although superior in model fit, 
prediction criteria indicate that OLS is relatively poor in prediction along the 
entire range of costs. CONCLUSIONS: OLS on untransformed Y cost model is 
selected as the best model choice under the conditions of the given distributions. 
The inability for all three models to predict within the full range of costs 
demonstrates weakness in characterizing the upper tail of the distribution. If 
prediction is the primary concern, a two-part model may be more appropriate.  
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OBJECTIVES: When modeling long-term costs and health effects using Markov 
models, choosing the time of transition to another state (progression of the 
disease) seems to influence the final results. Various approaches can be adopted, 
i.e. transitions at the beginning, at the end or in the middle of the cycle. Our aim 
is to measure influence of cycle length and progression rates on differences 
between final results obtained using those methods and to establish whether 
there is an optimal cycle length for which half cycle correction (HCC) should 
always be applied. METHODS: A simple, hypothetical, two-state Markov model 
was built. The time horizon was set to be lifetime, an outcome discount rate was 
0% or 5% and costs/utilities were held constant in time. Assuming different 
progression rates (0.05–0.90 annually), three methods were compared: transitions 
at the beginning of the cycle (‘beginning’), at the end of the cycle (‘end’), in the 
middle of the cycle (HCC). For each parameter the threshold values were 
determined, i.e. the maximal cycle length for which the difference between half-
cycle correction and ’beginning’/‘end’ methods were not greater than 5%. We 
assumed that cycles longer than the estimated threshold will imply the 
application of HCC. RESULTS: For 5% discount rate the threshold cycle length 
was 1 year for annual progression of 0.05 and it became shorter for lower 
progression rates (2 weeks for 0.90 progression rate). Assuming no discounting, 
the threshold was 2 years for annual progression of 0.05 and 2 weeks for 
progression of 0.90. CONCLUSIONS: Choice of the time of transitions in the 
model may have a significant impact on results. For cycles shorter than 2 weeks 
HCC does not seem to be necessary, however it should always be applied for 
cycles longer than 1 year. For cycles between 2 weeks and 1 year a general 
recommendation cannot be made.  
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OBJECTIVES: Health Technology Assessment (HTA) has during the last decades 
become an increasingly important tool for the introduction of new health care 
interventions. The aim of HTA is to assist payers in making informed decisions 
about allocating resources in the health care system. The use of decision-
analytic modelling (DAM) to aid HTA represents an explicit approach to 
synthesizing available evidence and provides support in reimbursement 
decisions under conditions of uncertainties. Probabilistic sensitivity analysis 
(PSA) is generally viewed as the most appropriate method of handling parameter 
uncertainty as it provides assessment of the joint effect of uncertainty over all 
ingoing parameters. It also facilitates value-of-information analysis that can 
quantify the implications of decision uncertainty explicitly and investigate the 
value of further studies. The objective of this study is to explore the value given 
to probabilistic decision modelling in the context of health technology 
assessment in England and Scandinavia. METHODS: A systematic search was 
undertaken to identify the current guidelines of the HTA bodies in England and 
Scandinavia (Sweden, Norway, and Denmark), specifically extracting all 
information relating to approaches of assessing uncertainties in DAM and the 
request for probabilistic analysis (e.g. incremental net benefit (INB) analysis or 
expected-value-of-perfect-information methods (EVP(P)I). RESULTS: All the 
reviewed HTA agencies and reimbursement authorities require deterministic 
sensitivity analysis for primary assumptions whereas only two agencies 
specifically require an addition of a PSA. The guidelines from the National 
Institute for health and Clinical Excellence (NICE) in the UK express strong 
support of conducting PSA, but have no requirements for the inclusion of EVP(P)I. 
The Norwegian Medicines Agency (NoMA) guidelines mentions both INB analysis 
and EVP(P)I. The remaining countries have no specific requirements regarding 
probabilistic modelling at all. CONCLUSIONS: The recent inclusion 
recommendations of INB and EVP(P)I in Norway indicate a growing recognition of 
the value of probabilistic analysis.  
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OBJECTIVES: Unlike modeling chronic diseases such as diabetes, ILS for oncology 
drugs health technology assessment (HTA) is rare because of short treatment 
duration, simple disease states and treatment pathways. With new drugs filling 
the space of mild symptomatic or asymptomatic cancer patients, researchers 
start to embrace the method of ILS because it can better predict survival and 
other events by individual patient tracking, and simulate trials and real world 
clinical practice. It has not been widely endorsed by HTA payers due to lack of 
simplicity and transparency. The objective of this study is to review and catalog 
different modeling methods used in NICE submissions for advanced/metastatic 
cancer treatments, understand when NICE is looking for ILS. METHODS: A 
targeted search of NICE website found 68 NICE rulings happened between 2000 
and 2012 for oncology drugs. We extracted information on the model used, the 
application setting, the method and data used to model cancer evolution. 
RESULTS: Survival trees and Markov cohort models were most commonly 
employed. Simulation methods evolved from simple decision trees to more 
complex Markov models over the last decade. ILS model was submitted to NICE 
for decision making by manufacturers. NICE stated that it would accept the 
discrete event simulation model, a type of ILS, if manufacturer made a well 
justified case. When multiple treatments and/or patient heterogeneity exist, and 
such complexity influences cost and health outcomes, NICE encouraged the 
method of ILS. For example, ILS was suggested in modeling the first line 
maintenance of Rituximab in treating the stage III-IV follicular lymphoma and 
first line treatment of Imatinib in treating metastatic gastro-intestinal stromal 
tumors. CONCLUSIONS: ILS emerges as a modeling method for cancer treatment 
because it provides a framework for natural representation of disease and 
resource use. Although it is a more sophisticated approach, some HTAs like NICE 
start to support this method.  
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OBJECTIVES: To suggest alterations to cost-effectiveness models of biologics for 
moderate to severe psoriasis that would account for the utility of partial 
responders. METHODS: Clinical guidelines dictate that, for the continuation of a 
biologic in treatment of moderate to severe psoriasis, a 75% improvement from 
baseline on the Psoriasis Area Severity Index (PASI) must be achieved which 
serves as a Minimum Clinical Endpoint (MCE). However, patients achieving a 
PASI 50% improvement may also continue treatment if supplemented by a 
minimally important difference (MID) in health-related quality of life (5-point 
improvement on the Dermatology Life Quality Index (DLQI)). Since cost-
effectiveness models of biologic medications for treatment of psoriasis do not 
account for the utility of any patients achieving a PASI 50% improvement, a 
systematic review was conducted to identify whether patients achieving a PASI 
50% improvement also achieved a 5-point DLQI improvement in large RCTs. 
Statistical inference from data obtained therein was used to modify equations 
used in cost-effectiveness calculations. RESULTS: The systematic review 
returned 8 studies that reported DLQI improvements in terms of Mean ± SD, 
stratified by increasing PASI response. Each study returned mean DLQI scores for 
patients with a PASI 50% improvement that were within one standard deviation 
of a 5-point DLQI improvement. This finding drove proposed alterations in which 
patients with a PASI 50% improvement are counted as “partial responders” or 
“non-responders” based on the probability of whether or not a 5-point DLQI 
improvement was attained. CONCLUSIONS: The literature confirms that 
patients with severe psoriasis can achieve a MID in DLQI improvement without 
achieving an MCE in PASI improvement. This study proposes alterations to the 
methodology of cost-effectiveness calculations that recognize the meaningful 
improvement in outcomes achieved by this subset of patients. Nevertheless, 
future studies should examine how these alterations affect overall cost-
effectiveness of biologics for psoriasis.  
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OBJECTIVES: To apply national demographic and epidemiologic data in China to 
a mathematical model designed to estimate the public health impact of PCV7 at 
a population level. METHODS: Demographic data were collected from 2008 
census .The incidence rate of all-cause hospitalized pneumonia and 
pneumococcal meningitis was searched from international literature. Data were 
applied to a 10-year Markov model to estimate the impact of vaccination on 
those diseases. Projections of the diseases over a 10-year period are estimated 
under assumptions of no vaccination and full vaccination of the national birth 
cohort. Details of the model calculations as applied to the United States were 
published elsewhere. RESULTS: According to model estimation, over 730,000 
cases of pneumococcal meningitis and over 100 million cases of pneumonia that 
would occur in unvaccinated children and adults in China over a 10-year period, 
as well as causing over 5.3 million deaths. More than 30 million cases and 
420,000 deaths would occur in children under 5 years of age. The inclusion of 
universal vaccination of infants with PCV7 was expected to reduce the overall 
burden by 5.5 million cases, largely due to the reduction in all-cause pneumonia, 
with nearly 2 million cases of pneumonia estimated to be reduced in children 
under 5 years old. CONCLUSIONS: Widespread use of PCV7 in China is expected 
to have a significant impact on hospitalizations and death due to all-cause 
pneumonia and meningitis in vaccinated children.The potential impact of 
widespread use of PCV7 on unvaccinated persons due to herd protection adds to 
the overall public health impact significantly.  
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OBJECTIVES: The traditional audience for US health economic (HE) models has 
been payers, but the changing health care reimbursement environment suggests 
a stronger role for provider-perspective models. The US health care system is 
moving toward quality incentive payment schemes and increased risk sharing 
for providers. This shift in payment will impact provider incentives and priorities 
as they relate to technology adoption. Here, we look at how the transition from 
fee-for-service payments to bundled payments in accountable care organizations 
(ACO) will impact health economic modeling for manufacturers of medical 
devices. METHODS: Expert analysis was conducted on a comprehensive review 
of publicly available literature, in-depth discussions with hospital and ACO 
administrators, and drawing on lessons learned from developing models for 
device manufacturers. Relevant model inputs, time horizon, outcomes and 
structure were examined to provide recommendations for improving the 
usefulness of HE models for hospital and ACO decision-makers. RESULTS: Of the 
6 administrators interviewed, 5 (83.3%) felt that technology adoption decisions 
will move beyond the individual physician and extend to the system-wide level. 
When asked to consider what outputs would be most useful for benefit design 
and coverage decision-making, administrators cited the total cost of procedure 
(include hospital length-of-stay and hospital resource utilization), post-operative 
care and cost associated with complications from the procedure, in rank order. 
ACO administrators reported that time horizons considered as part of budget 
impact modeling should be extended from the traditional benefit year to up to 3 
years, depending on the length of the episode of care. CONCLUSIONS: Medical 
device manufacturers need to create data and tools  
that demonstrate efficiency gains and cost-effectiveness from a hospital and 
ACO purchasing strategy. The ability to demonstrate both a clinical and 
economic value to hospitals and ACOs, who are increasingly the key decision-
makers for technology adoption, will be important to achieving successful 
market access.  
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OBJECTIVES: Where data is sparse, expert opinion may be used to populate 
decision analytic models. Elicitation techniques which capture uncertainty 
associated with expert opinion (i.e. elicit probability distributions) have analytic 
benefits over obtaining single values from experts but may be difficult to carry 
out and the methodological implications of different techniques are poorly 
understood. To assess current use of elicitation techniques which incorporate 
experts’ uncertainty, we conducted a methodological review of the use of 
elicitation in economic models. METHODS: The review was systematic in 
approach. Electronic databases (MEDLINE, EMBASE and CRD) were searched 
using an explicit strategy. Studies describing their approach to elicitation were 
included. Data was abstracted on pre-defined aspects of the elicitation 
technique. The synthesis was narrative. RESULTS: Twelve articles were included. 
The median number of experts per study was five (range 3-23). In eleven studies 
(91.7%), experts were asked individually. Only one study reported a group 
elicitation exercise. The most frequently used approaches to elicitation were the 
histogram technique and the bisection method. Elicitation was used to inform 
effectiveness (for treatments), performance (for diagnostic tests) or disease 
progression parameters, with only one study eliciting resource use. The elicited 
parameters were in the form of a proportion in seven studies, time to event in 
four studies, rate in three and relative risk in two studies. Across these studies, 
there was heterogeneity in both approach and reporting of what we considered 
to be key aspects of the elicitation process. CONCLUSIONS: Judged by the studies 
identified in the review, elicitation can be useful and is valued. Efforts should be 
made to improve reporting of elicitation in health technology assessments, with 
the aim of not only of improving the description of individual studies, but also to 
contribute towards establishing accepted good practice in elicitation in the 
context of decision analytic modeling.  
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OBJECTIVES: To figure out what disease models equations/hypothesis work best 
on what populations. METHODS: 1) Extraction of multiple published disease 
models/risk equations for cardiovascular disease and multiple diabetic 
population distributions and outcomes. The populations used were UKPDS, 
ASPEN, ADVANCE, ACCORD, NDR, KP. 2) Implementation of these components 
and systematic cross validation of models against populations using micro-
simulation and relying on computing power. 3) Defining a fitness score to 
convert of multiple outcome differences into a single number. 4) Defining 
different queries with weights to rank model / population fitness. The methods 
avoid using individual data and rely on more accessible summary data. 
RESULTS: The fitness score matrix uses color coding and ranking to visually 
demonstrate the fitness between 6/34 populations/cohorts and 64 combinations 
of published risk equations and hypotheses. The results show that different 
combinations of risk equations behave differently on different population 
cohorts. For each query, the system ranks the models. Models that implement 
the following two corrections generally behaved better: 1) Temporal correction 
for treatment improvement; 2) Biomarker change introduced in the first year. 
CONCLUSIONS: 1) Modelers should talk in terms of best fitting model rather than 
best model since in many cases, the best model changes according to specifics of 
the query. 2) Disease modelers who develop risk equations should add a 
temporal correction term within their risk equations to prevent model outdating. 
3) The fitness score function allows comparing behavior of different populations 
using a similar metric and provides a visual explanation of current 
understanding of disease progression.  
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OBJECTIVES: In the spectrum of methodologies used to conduct economic 
evaluations, patient-level simulation modeling is noteworthy for its flexibility in 
reproducing patient experiences that closely mirror reality. This flexibility is 
especially important when modeling diseases with continuous or multi-
dimensional health states or with non-Markovian dependence on disease 
history, but often comes at the expense of advanced data and software 
requirements and reduced computational efficiency. Methods for exploiting the 
opportunities while mitigating the challenges associated with using simulation 
modeling are needed. METHODS: Based on our experience developing patient-
level simulation models in Microsoft Excel for a complex, progressive disease, we 
identified steps that can be taken during the development and presentation of a 
simulation model to capitalize on the advantages inherent in the flexibility and 
transparency of this approach while mitigating some of the the associated 
